GlassScriptPhysician profile
Edward A Alquero
NPI 1578610168
$23,814.92
in general payments reported to CMS, 2019-2025
34 companies · $3,808 in 2025
The $3,808 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,256 · 2020: $3,207 · 2021: $3,797 · 2022: $1,292 · 2023: $3,939 · 2024: $3,515 · 2025: $3,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,241.79 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,759.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Insmed, INC. | $2,837.45 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $2,378.47 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Glaxosmithkline, LLC. | $1,893.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,808.93 | 2019-2025 | Tepezza, Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,366.65 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,283.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $1,111.99 | 2019-2023 | Krystexxa, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $985.19 | 2021-2025 | |
| Amarin Pharma, INC. | $960.59 | 2019-2023 | |
| Lilly USA, LLC | $958.40 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $752.48 | 2019-2024 | |
| Gilead Sciences, INC. | $465.77 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $459.85 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $412.14 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $371.12 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $329.57 | 2019-2023 | Xarelto |
| Allergan, INC. | $259.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $204.10 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $201.01 | 2019-2023 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $150.73 | 2024-2025 | Rexulti |
| Dexcom, INC. | $143.54 | 2024-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $139.14 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $126.37 | 2019-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $117.36 | 2019-2023 | Eliquis |
| Vanda Pharmaceuticals INC. | $94.92 | 2025 | Fanapt |
| Astellas Pharma US INC | $47.55 | 2019 | |
| Insulet Corporation | $43.49 | 2024-2025 | Omnipod |
| Avanir Pharmaceuticals, INC. | $39.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.39 | 2019 | |
| Leo Pharma INC. | $23.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.60 | 2024 | Caplyta |
| Ironwood Pharmaceuticals, INC | $20.25 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Alquero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.